Ambergen In the News
PressJuly 2008Paper published in Analytical Biochemistry on Ambergen's novel technology "Photocleavage Based Affinity Purification and Printing of Cell-Free Expressed Proteins: Application to Proteome Microarrays"AnnouncementsSeptember 2008Ambergen receives US patent #7,423,122 on its T2 ELISA technologyJuly 2008NIH-NCI announces $1.2 million Phase II SBIR Award for Ambergen to develop and commercialize a high sensitivity drug resistance assay for CML patientsJune 2008Ambergen signs agreement with Ananomouse, Inc. to develop cancer recurrence assaysMarch 2008Ambergen receives US patent #7,339,045 on novel PC-linker technology for DNA sequencing and protein detectionDecember 2007Ambergen receives two US patents (#7,312,060 and 7,312,038) on its protein detection and isolation technology with broad applications including DNA sequencingNovember 2007Dr. Mark Lim, Director of Proteomics, co-chairs the Advances in Proteomics: New Technologies I Session at the 2007 Annual Meeting of the American Electrophoresis Society in Salt Lake City, UT and also delivers talk on cell-free expressed proteomicsNovember 2007Ambergen opens new corporate headquarters and laboratories in Watertown, MAOctober 2007Ambergen receives US patent #7,288,372 on new methods to create designer proteins by TRAMPE for biomedical applicationsSeptember 2007NCI-NIH announces $1.3 million Phase I SBIR Award for Ambergen to develop prognostic CRC assays based on molecular profiling of tumorsAugust 2007Ambergen receives US patent #7,252,932 on methods to detect protein truncations using gel-free methodsAugust 2007Dr. Christopher Sears joins Ambergen, Inc. as CSOMay 2007Ambergen receives US patent # 7,211,394 and # 7,195,874 on methods of using its proprietary photocleavable linkersApril 2007NIAID-NIH announces $2.5 million Phase II SBIR Award to Ambergen to develop and commercialize high sensitivity HIV drug resistance assaysMarch 2007NIAID-NIH announces $2.0 million Phase II SBIR Award for Ambergen to develop and commercialize diagnostic assays for autoimmune diseaseFebruary 2007Dr. James Han joins Ambergen as Director of New Assay DevelopmentJanuary 2007Ambergen receives US patent #7,169,558 for its TRAMPE technology |
©2009 Ambergen Inc. All Rights Reserved. Terms & Conditions